Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates GlobeNewswire - Thu Mar 5, 6:03AM CST

Achieved Q4 2025 PEMGARDA ® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter 2025 year-end cash and cash equivalents of...

IVVD : 1.8000 (+3.45%)
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer GlobeNewswire - Thu Mar 5, 6:01AM CST

Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital,...

IVVD : 1.8000 (+3.45%)
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 GlobeNewswire - Mon Mar 2, 3:10PM CST

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced...

IVVD : 1.8000 (+3.45%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Mar 2, 3:01PM CST

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an...

IVVD : 1.8000 (+3.45%)
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies GlobeNewswire - Tue Feb 24, 6:01AM CST

“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published...

IVVD : 1.8000 (+3.45%)
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration GlobeNewswire - Tue Feb 3, 6:01AM CST

LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to...

IVVD : 1.8000 (+3.45%)
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention GlobeNewswire - Thu Jan 22, 6:01AM CST

The educational campaign will focus on teaching the American public about antibodies and preventing infectious disease The collaboration will advance public understanding of antibodies as a centerpiece...

IVVD : 1.8000 (+3.45%)
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 GlobeNewswire - Tue Jan 20, 6:01AM CST

Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injury Participants to include people with...

IVVD : 1.8000 (+3.45%)
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights GlobeNewswire - Thu Jan 8, 6:01AM CST

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter Preliminary ending 2025 cash and cash equivalents...

IVVD : 1.8000 (+3.45%)
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID GlobeNewswire - Tue Dec 23, 2025

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational...

IVVD : 1.8000 (+3.45%)

Barchart Exclusives

1 Little-Known Tech Stock That Wedbush Calls a Must-Own Amid Middle East Conflict Barchart - Sat Mar 7, 10:30AM CST
Check Point emerges as a must-own cybersecurity stock amid Middle East tensions, offering stable AI-driven growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot